7:01 AM ET
8-K
Investor Presentation
Aldeyra Therapeutics Investor Presentation
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.
- Counterparty
- FDA